|
Category:pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 255.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 594.97 °C. @ 760.00 mm Hg (est)
|
| Vapor Pressure: | 7.500000 mmHg @ 25.00 °C. (est) |
| Flash Point: | 597.00 °F. TCC ( 313.60 °C. ) (est)
|
| logP (o/w): | -0.617 (est) |
| Soluble in: |
| | water, 3.399e+004 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-child TDLo 3000 mg/kg/22W-I
BLOOD: AGRANULOCYTOSIS
BLOOD: THROMBOCYTOPENIA
American Journal of Emergency Medicine. Vol. 16, Pg. 396, 1998.
intravenous-mammal (species unspecified) LD50 400 mg/kg
Pharmacy International. Vol. 5, Pg. 191, 1984.
intravenous-man TDLo 134 ug/kg/1D-I
BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"
Lancet. Vol. 2, Pg. 385, 1985.
intravenous-man TDLo 107 mg/kg/4D-I
KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"
American Journal of Kidney Diseases. Vol. 22, Pg. 611, 1993.
oral-man TDLo 486 mg/kg/17D-
GASTROINTESTINAL: OTHER CHANGES
GASTROINTESTINAL: DECREASED MOTILITY OR CONSTIPATION
American Journal of Gastroenterology. Vol. 88, Pg. 2110, 1993.
intraperitoneal-mouse LD50 724 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994.
intravenous-mouse LD50 1118 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
oral-mouse LD50 > 10000 mg/kg
Nature. Vol. 272, Pg. 583, 1978.
intraperitoneal-rat LD50 860 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
intravenous-rat LD50 750 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994.
oral-rat LD50 > 20000 mg/kg
Drugs in Japan Vol. -, Pg. 7, 1990.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 1118 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
subcutaneous-rat LD50 620 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | pharmaceuticals / chemical synthisis |
| Recommendation for acyclovir usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for acyclovir flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 2022 |
| Pubchem (sid): | 135005619 |
Other Information:
| (IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
| Videos: | The Periodic Table of Videos |
| tgsc: | Atomic Weights use for this web site |
| (IUPAC): | Periodic Table of the Elements |
| CHEBI: | View |
| CHEMBL: | View |
| KEGG (GenomeNet): | C06810 |
| HMDB (The Human Metabolome Database): | HMDB14925 |
| MedlinePlusSupp: | View |
| ChemSpider: | View |
| Wikipedia: | View |
Formulations/Preparations:
•topical: ointment: 5%, zovirax (biovail)
•oral: capsules: 200 mg zovirax (with parabens), (glaxosmithkline); suspension: 200 mg5ml acyclovir suspension (with parabens), (alpharma), zovirax (with glycerin parabens and sorbitol), (glaxosmithkline); tablets: 400 mg zovirax (with povidone), glaxosmithkline, 800 mg zovirax (with povidone), glaxosmithkline.
•acyclovir sodium: parenteral: for injection, concentrate, for iv infusion only: 25 mg (of acyclovir) per ml (500 mg, 1 g) acyclovir sodium injection (mayne), 50 mg (of acyclovir) per ml (500 mg, 1 g) acyclovir sodium injection (american pharmaceutical partners), for injection, for iv infusion only: 500 mg (of acyclovir) acyclovir sodium for injection (abbott, american pharmaceutical partners, bedford), zovirax (glaxosmithkline), 1 g (of acyclovir) acyclovir sodium for injection (abbott, bedford), zovirax (glaxosmithkline).
|
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | aciclovier | | | acyclo-V | | | alti-acyclovir | | 2- | amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one | | 2- | amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one | | 2- | amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one | | 2- | amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one | | 2- | amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one | | 2- | amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one | | 2- | amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one | | 2- | amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one | | | azone | | | cargosil | | | cyclovir | | | genvir | | | gerpevir | | | herpevir | | 9-[(2- | hydroxyethoxy)-methyl]guanine | | 9-((2- | hydroxyethoxy)methyl)guanine | | 9-[(2- | hydroxyethoxy)methyl]guanine | | 9-(2- | hydroxyethoxy)methylguanine | | 9-(2- | hydroxyethyloxymethyl)guanine | | 9- | hyroxyethoxymethylguanine | | | maynar | | | poviral | | 6H- | purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- | | 6H- | purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- | | | vipral | | | viropump | | | virorax | | | viroraxl | | | zovir | | | zovirax | | | zyclir |
Articles:
| PubMed:Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. |
| PubMed:Development of performance matrix for generic product equivalence of acyclovir topical creams. |
| PubMed:Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. |
| PubMed:Comparison of in vitro release rates of acyclovir from cream formulations using vertical diffusion cells. |
| PubMed:Electrosprayed core-shell solid dispersions of acyclovir fabricated using an epoxy-coated concentric spray head. |
| PubMed:Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB. |
| PubMed:The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007. |
| PubMed:The antiviral drug valacyclovir successfully suppresses salivary gland hypertrophy virus (SGHV) in laboratory colonies of Glossina pallidipes. |
| PubMed:Biological activities of purified marennine, the blue pigment responsible for the greening of oysters. |
| PubMed:Tsetse salivary gland hypertrophy virus: hope or hindrance for tsetse control? |
| PubMed:Screening method for the analysis of antiviral drugs in poultry tissues using zwitterionic hydrophilic interaction liquid chromatography/tandem mass spectrometry. |
| PubMed:Inhibitory effect of caffeic acid on human organic anion transporters hOAT1 and hOAT3: a novel candidate for food-drug interaction. |
| PubMed:The effect of emodin, an anthraquinone derivative extracted from the roots of Rheum tanguticum, against herpes simplex virus in vitro and in vivo. |
| PubMed:Analysis of the antiviral drugs acyclovir and valacyclovir-hydrochloride in tsetse flies (Glossina pallidipes) using LC-MSMS. |
| PubMed:Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults. |
| PubMed:Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets. |
| PubMed:The treatment of herpes simplex infections: an evidence-based review. |
| PubMed:Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). |
| PubMed:Radiesse-induced herpes zoster. |
| PubMed:Antiviral activity of esterified alpha-lactalbumin and beta-lactoglobulin against herpes simplex virus type 1. Comparison with the effect of acyclovir and L-polylysines. |
| PubMed:Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. |
| PubMed:Chickenpox. |
| PubMed:Genital herpes. |
| PubMed:Topical Cidofovir for Treatment of Resistant Viral Infections. |
| PubMed:Herpes labialis. |
| PubMed:Developing an evidence-based, preventive care package for persons with HIV in Africa. |
| PubMed:Exposure-response relationships and drug interactions of sirolimus. |
| PubMed:Assessing bioequivalence using genomic data. |
| PubMed:First one-day, oral antiviral for cold sores is approved. |
| PubMed:Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. |
| PubMed:Pediatric uses of valacyclovir, penciclovir and famciclovir. |
| PubMed:Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. |
| PubMed:Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. |
| PubMed:Drug-resistant herpes: cidofovir gel in limbo. Interview with Jay Lalezari, M.D. Interview by John S. James. |
| PubMed:[Primary varicella-zoster virus infection--current knowledge, diagnostic and therapeutic approaches]. |
| PubMed:Perspectives on switching oral acyclovir from prescription to over-the-counter status: report of a consensus panel. |
| PubMed:Cidofovir use in acyclovir-resistant herpes infection. |
| PubMed:Foscavir receives new indication. |
| PubMed:New drug approvals in 1996. |
| PubMed:The pharmacological profile of famciclovir. |
| PubMed:Drug effective against herpes. |
| PubMed:New drugs--reports of new drugs recently approved by the FDA. Valacyclovir. |
| PubMed:Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers. |
| PubMed:Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG). |
| PubMed:From the Food and Drug Administration. |
| PubMed:Uses and safety of acyclovir in pregnancy. |
| PubMed:Pregnancy outcomes following systemic prenatal acyclovir exposure--June 1, 1984-June 30, 1993. |
| PubMed:Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. |
| PubMed:Clinical relevance of herpes simplex virus in the throat of elderly with Salmonella enteritidis gastroenteritis. |
| PubMed:[Prevention against chickenpox in children is unnecessary!]. |
| PubMed:Acyclovir approved for childhood chickenpox. |
| PubMed:From the Food and Drug Administration. |
| PubMed:From the Food and Drug Administration. |
| PubMed:[Prevention of bacterial infections after bone marrow graft by broad-spectrum oral antibiotics, absorbable (pefloxacin, penicillin) and non absorbable (cephalosporin, gentamycin, bacitracin)]. |
| PubMed:Open study of 2-amino-9-(hydroxyethoxymethyl)-9H-purine (desciclovir) in the treatment of herpes zoster. |
| PubMed:Evaluation of drug reviews. |
| PubMed:Oral form of acyclovir approved. |
| PubMed:Mutagenicity in drug development: interpretation and significance of test results. |
| PubMed:Acyclovir. |
| PubMed:New anti-herpes virus drug being tested. |
|
3D/inchi